EGFR and neoplasm: First, never-smokers harbour markedly fewer tobacco-related passenger mutations and a lower prevalence of resistance-associated co-mutations such as TP53, STK11 and RB1, which are enriched in smoking-related tumours and accelerate escape from EGFR blockade (Moorthi et al., 2024; Labbe et al., 2017).